Bile Acid Metabolism Subtypes Reveal Immune Dysfunction in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with over two million new cases and nearly one million deaths annually. While immune checkpoint inhibitors (ICIs) have heralded a significant advance in the management of CRC—especially in cases exhibiting high microsatellite instability (MSI-H)—the majority of patients experience primary resistance to these agents. Understanding the molecular determinants that contribute to this resistance and the complex interplay between tumor metabolism and immunity is central to improving therapeutic outcomes. Bile acids, beyond their established role in lipid digestion, have emerged as critical modulators of tumor biology and the tumor immune microenvironment (TIME). However, the specific pathways by which bile acid metabolism shapes tumor immunity and patient prognosis in CRC have not been fully delineated.

Key Innovation from the Reference Study

The study by Feng et al. (2026) introduces an integrative transcriptomic subtyping of CRC based on bile acid metabolism gene expression. By stratifying tumors into bile acid metabolism-high and -low subtypes, the authors identify a mechanistic link between altered bile acid pathways and immune dysfunction within the tumor microenvironment. Importantly, the study pinpoints three genes—CLCA1, UGT2A3, and ZG16—as downregulated markers in CRC associated with immune cell infiltration and patient survival. This work bridges metabolic and immunological profiling, enabling refined risk classification and potentially guiding future biomarker-driven interventions.

Methods and Experimental Design Insights

To dissect the influence of bile acid metabolism on CRC biology, the authors conducted a comprehensive bioinformatics analysis using transcriptome and clinical data from The Cancer Genome Atlas-Colon Adenocarcinoma (TCGA-COAD) cohort. Unsupervised consensus clustering based on bile acid metabolism-related genes enabled the classification of patients into distinct molecular subtypes. Differentially expressed genes (DEGs) and immune cell infiltration patterns were compared between subtypes using established computational methods, such as CIBERSORT and TIMER. Hub genes were identified through protein–protein interaction (PPI) network analysis and Cox proportional hazards modeling. These candidate markers were subsequently validated in external Gene Expression Omnibus (GEO) datasets and an independent clinical cohort, ensuring reproducibility and translational relevance.

Protocol Parameters

• RNA source and extraction: Fresh-frozen CRC tissue samples and paired normal tissues; standard column-based isolation protocols.
• Transcriptome profiling: RNA-seq (Illumina platform) with normalization to FPKM or TPM; cross-validation with GEO datasets (GSE39582, GSE17536).
• Consensus clustering: Unsupervised clustering using bile acid metabolism gene set (from MSigDB); optimal cluster number determined by CDF and silhouette analysis.
• Immune infiltration analysis: CIBERSORT and TIMER algorithms to quantify immune cell subtypes, with statistical comparison between bile-high and bile-low groups.
• Differential gene expression: Limma package for DEG identification (adjusted p-value < 0.05, |log2FC| > 1).
• Hub gene validation: mRNA expression of CLCA1, UGT2A3, and ZG16 measured by qPCR and immunohistochemistry in independent patient samples.
• Survival analysis: Kaplan-Meier plot and Cox regression for overall survival association.

Core Findings and Why They Matter

The bile-low CRC subtype exhibited significantly reduced overall survival compared to the bile-high group (p = 0.0049), as reported in the reference study. Notably, the bile-low group showed increased infiltration of CD8+ T cells (p < 0.05) and M1 macrophages (p < 0.01), a paradoxical finding suggesting that immune infiltration does not always equate to effective anti-tumor immunity. Instead, these tumors may be characterized by dysfunctional immune responses, potentially due to regulatory pathways shaped by bile acid metabolism.

Three genes—CLCA1, UGT2A3, and ZG16—were consistently downregulated in tumor tissues across both TCGA and GEO datasets, as well as in independent clinical samples. High expression of CLCA1 was a robust predictor of improved overall survival (p < 0.001), while UGT2A3 and ZG16 did not reach individual statistical significance for survival association. All three genes demonstrated negative correlations with TIDE (Tumor Immune Dysfunction and Exclusion) scores, indicating a potential mechanistic role in modulating immune evasion. These findings suggest that bile acid metabolism, via regulation of specific gene networks, shapes the TIME and influences both prognosis and response to immunotherapy in CRC.

Comparison with Existing Internal Articles

Several internal resources contextualize the implications of bile acid metabolism and gene expression analysis in CRC. The article "Bile Acid Metabolism Genes Mark Immune Dysfunction in CRC" provides an accessible overview of how CLCA1, UGT2A3, and ZG16 serve as metabolic-immune biomarkers, reinforcing the core message of the reference study. For laboratory workflows, "HyperScript III RT SuperMix: Advancing Precision qPCR in CRC Research" and "Reliable Gene Expression Analysis with HyperScript™ III RT SuperMix" discuss critical technical challenges in quantifying low-abundance and high-GC transcripts, a common issue when validating markers like CLCA1 and ZG16. These resources highlight the importance of sensitive reverse transcription, effective genomic DNA removal, and robust qPCR assay design in biomarker studies.

Limitations and Transferability

While the study demonstrates strong associations between bile acid metabolism subtypes, immune cell infiltration, and patient outcomes, several limitations should be noted. The observational nature of transcriptome analyses constrains causal inference; functional studies are required to determine whether modulating CLCA1, UGT2A3, or ZG16 expression directly alters tumor immunity or therapy response. Furthermore, the bile acid metabolic signature may not capture the full spectrum of tumor heterogeneity, and external validation in prospective, multi-center cohorts is warranted. The generalizability of findings to non-Asian populations and across CRC molecular subtypes (e.g., MSI-H versus MSS) remains to be established.

Research Support Resources

Researchers aiming to validate gene expression markers in CRC, especially those working with low-copy or high-GC content RNA, can benefit from advanced reverse transcription solutions. HyperScript™ III RT SuperMix for qPCR (with gDNA wiper) (SKU K1585) from APExBIO is formulated to enhance reverse transcription efficiency, minimize genomic DNA contamination, and ensure robust cDNA synthesis for accurate qPCR-based gene expression analysis. The inclusion of a gDNA wiper mix is particularly advantageous for workflows requiring high sensitivity and specificity, such as those validating metabolic and immune markers in clinical CRC samples.